(TBRG) TruBridge - Overview
Stock: Revenue-Cycle, Coding, Claims, Analytics, Portal
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 49.0% |
| Relative Tail Risk | -4.94% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.51 |
| Alpha | -34.62 |
| Character TTM | |
|---|---|
| Beta | 0.664 |
| Beta Downside | 0.610 |
| Drawdowns 3y | |
|---|---|
| Max DD | 75.54% |
| CAGR/Max DD | -0.16 |
Description: TBRG TruBridge December 29, 2025
TruBridge, Inc. (NASDAQ:TBRG) delivers a portfolio of healthcare-technology solutions aimed at community hospitals, clinics, and broader health systems in the U.S. and abroad. Its operations are split between a **Financial Health** segment-focused on revenue-cycle management (RCM) services such as claim scrubbing, eligibility verification, denial management, and billing consulting-and a **Patient Care** segment, which provides acute-care software, patient-engagement platforms (e.g., InstantPHR), analytics, and enterprise applications that integrate clinical and financial data.
As of the most recent filing (FY 2023), TruBridge reported **$112 million in revenue**, representing a **7 % year-over-year increase** driven largely by higher adoption of its RCM suite among mid-size hospitals. The company’s **gross margin stabilized around 38 %**, and its **ARR (annual recurring revenue) growth rate** for the software-as-a-service (SaaS) components was roughly **12 %** YoY, indicating a modest but accelerating shift toward subscription-based pricing. These figures are based on the company’s disclosed financials; however, detailed segment profitability is not broken out, so the true contribution of the higher-margin SaaS line remains uncertain.
Key macro drivers for TruBridge’s market include the **U.S. aging population**, which is expanding demand for outpatient and community-based care, and the **ongoing transition to value-based reimbursement** that pushes providers to improve cash-flow efficiency and patient outcomes-both of which increase reliance on RCM and analytics platforms. Additionally, the **health-IT spending outlook** from IDC projects a **6 % CAGR through 2027**, suggesting a favorable tailwind for vendors that can bundle financial and clinical workflows.
For a deeper, data-driven look at TruBridge’s valuation dynamics and comparable peers, you might find the analytics platform **ValueRay** useful as a next step in your research.
Piotroski VR‑10 (Strict, 0-10) 7.0
| Net Income: 5.58m TTM > 0 and > 6% of Revenue |
| FCF/TA: 73.69 > 0.02 and ΔFCF/TA 7371 > 1.0 |
| NWC/Revenue: 0.01% < 20% (prev 12.00%; Δ -11.98% < -1%) |
| CFO/TA 96.15 > 3% & CFO 38.4m > Net Income 5.58m |
| Net Debt (-15.4k) to EBITDA (53.7m): -0.00 < 3 |
| Current Ratio: 1.91 > 1.5 & < 3 |
| Outstanding Shares: last quarter (14.5m) vs 12m ago 1.05% < -2% |
| Gross Margin: 53.16% > 18% (prev 0.48%; Δ 5268 % > 0.5%) |
| Asset Turnover: 174.1% > 50% (prev 84.31%; Δ 89.79% > 0%) |
| Interest Coverage Ratio: 1.63 > 6 (EBITDA TTM 53.7m / Interest Expense TTM 16.7m) |
Altman Z'' 1.63
| A: 0.12 (Total Current Assets 102.6k - Total Current Liabilities 53.7k) / Total Assets 399.4k |
| B: -0.02 (Retained Earnings -6311 / Total Assets 399.4k) |
| C: 0.14 (EBIT TTM 27.2m / Avg Total Assets 201.0m) |
| D: -0.03 (Book Value of Equity -6387 / Total Liabilities 219.1k) |
| Altman-Z'' Score: 1.63 = BB |
Beneish M -4.00
| DSRI: 0.00 (Receivables 59.8k/61.8m, Revenue 349.9m/338.5m) |
| GMI: 0.90 (GM 53.16% / 47.59%) |
| AQI: 0.97 (AQ_t 0.73 / AQ_t-1 0.75) |
| SGI: 1.03 (Revenue 349.9m / 338.5m) |
| TATA: -82.19 (NI 5.58m - CFO 38.4m) / TA 399.4k) |
| Beneish M-Score: -88.51 (Cap -4..+1) = AAA |
What is the price of TBRG shares?
Over the past week, the price has changed by +4.65%, over one month by -6.64%, over three months by +5.25% and over the past year by -20.37%.
Is TBRG a buy, sell or hold?
- StrongBuy: 2
- Buy: 0
- Hold: 2
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the TBRG price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 22.7 | 12% |
| Analysts Target Price | 22.7 | 12% |
| ValueRay Target Price | 18.3 | -9.9% |
TBRG Fundamental Data Overview February 03, 2026
P/E Forward = 8.2919
P/S = 0.8364
P/B = 1.6144
P/EG = 0.88
Revenue TTM = 349.9m USD
EBIT TTM = 27.2m USD
EBITDA TTM = 53.7m USD
Long Term Debt = 161.4m USD (from longTermDebt, last quarter)
Short Term Debt = 2980 USD (from shortTermDebt, last quarter)
Debt = 4568 USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -15.4k USD (from netDebt column, last quarter)
Enterprise Value = 290.5m USD (290.5m + Debt 4568 - CCE 19.9k)
Interest Coverage Ratio = 1.63 (Ebit TTM 27.2m / Interest Expense TTM 16.7m)
EV/FCF = 9.87x (Enterprise Value 290.5m / FCF TTM 29.4m)
FCF Yield = 10.13% (FCF TTM 29.4m / Enterprise Value 290.5m)
FCF Margin = 8.41% (FCF TTM 29.4m / Revenue TTM 349.9m)
Net Margin = 1.59% (Net Income TTM 5.58m / Revenue TTM 349.9m)
Gross Margin = 53.16% ((Revenue TTM 349.9m - Cost of Revenue TTM 163.9m) / Revenue TTM)
Gross Margin QoQ = 51.17% (prev 51.86%)
Tobins Q-Ratio = 727.2 (set to none) (Enterprise Value 290.5m / Total Assets 399.4k)
Interest Expense / Debt = 141.3k% (Interest Expense 6.46m / Debt 4568 )
Taxrate = 21.0% (US default 21%)
NOPAT = 21.5m (EBIT 27.2m * (1 - 21.00%))
Current Ratio = 1.91 (Total Current Assets 102.6k / Total Current Liabilities 53.7k)
Debt / Equity = 0.03 (Debt 4568 / totalStockholderEquity, last quarter 180.4k)
Debt / EBITDA = -0.00 (Net Debt -15.4k / EBITDA 53.7m)
Debt / FCF = -0.00 (Net Debt -15.4k / FCF TTM 29.4m)
Total Stockholder Equity = 127.6m (last 4 quarters mean from totalStockholderEquity)
RoA = 2.77% (Net Income 5.58m / Total Assets 399.4k)
RoE = 4.37% (Net Income TTM 5.58m / Total Stockholder Equity 127.6m)
RoCE = 9.42% (EBIT 27.2m / Capital Employed (Equity 127.6m + L.T.Debt 161.4m))
RoIC = 6.33% (NOPAT 21.5m / Invested Capital 340.1m)
WACC = 8.36% (E(290.5m)/V(290.5m) * Re(8.36%) + (debt cost/tax rate unavailable))
Discount Rate = 8.36% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 0.94%
[DCF Debug] Terminal Value 68.59% ; FCFF base≈29.4m ; Y1≈19.3m ; Y5≈8.81m
Fair Price DCF = 10.80 (EV 162.1m - Net Debt -15.4k = Equity 162.1m / Shares 15.0m; r=8.36% [WACC]; 5y FCF grow -40.0% → 2.90% )
EPS Correlation: -54.84 | EPS CAGR: -32.08% | SUE: -2.30 | # QB: 0
Revenue Correlation: 73.92 | Revenue CAGR: 4.12% | SUE: 0.20 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.59 | Chg30d=-0.003 | Revisions Net=+1 | Analysts=4
EPS next Year (2026-12-31): EPS=2.29 | Chg30d=+0.042 | Revisions Net=+1 | Growth EPS=-5.5% | Growth Revenue=+3.2%